At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
WGS GeneDx Holdings
Post-Mkt 05-13 18:17:47 EDT
38.94
-0.55
-1.39%
盘后38.80
-0.14-0.36%
17:45 EDT
High39.85Low37.72Vol1.15M
Open38.56D1 Closing39.49Amplitude5.39%
Mkt Cap1.16BTradable Cap826.82MTotal Shares29.68M
T/O45.00MT/O Rate5.43%Tradable Shares21.23M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Corvex’s Keith Meister buys $48.44 million GeneDx common shares
Reuters  ·  05-12 09:22
Corvex’s Keith Meister buys $48.44 million GeneDx common shares
Stock Track | GeneDx Holdings Plummets 5.57% Intraday as Alphabet Dissolves Stake
Stock Track  ·  05-08
Stock Track | GeneDx Holdings Plummets 5.57% Intraday as Alphabet Dissolves Stake
Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Reuters  ·  05-08
Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Why Is GeneDx Stock Surging Thursday?
Benzinga  ·  05-08
Why Is GeneDx Stock Surging Thursday?
GeneDx Holdings Corp : Piper Sandler Cuts Target Price to $50 From $130
THOMSON REUTERS  ·  05-07
GeneDx Holdings Corp : Piper Sandler Cuts Target Price to $50 From $130
If AI Reshapes Healthcare, These Three Stocks Could Lead
Simply Wall St.  ·  05-06
If AI Reshapes Healthcare, These Three Stocks Could Lead
BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
Reuters  ·  05-06
BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
Stock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut
Stock Track  ·  05-05
Stock Track | GeneDx Holdings Plummets 46.19% in Pre-Market on Q1 Revenue Miss and Drastic Full-Year Guidance Cut
GeneDx price target lowered to $85 from $153 at Craig-Hallum
TIPRANKS  ·  05-05
GeneDx price target lowered to $85 from $153 at Craig-Hallum
Top Premarket Decliners
MT Newswires Live  ·  05-05
Top Premarket Decliners
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
GlobeNewswire  ·  05-05
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
GeneDx Holdings Is Maintained at Buy by BTIG
Dow Jones  ·  05-05
GeneDx Holdings Is Maintained at Buy by BTIG
Piper Sandler Remains a Buy on GeneDx Holdings (WGS)
TIPRANKS  ·  05-05
Piper Sandler Remains a Buy on GeneDx Holdings (WGS)
GeneDx Falls Premarket After Company Slashes '26 Rev View
Dow Jones  ·  05-05
GeneDx Falls Premarket After Company Slashes '26 Rev View
GeneDx Shares Slump 41.5% Premarket to $39.71 After Co Trims FY REV Outlook
THOMSON REUTERS  ·  05-05
GeneDx Shares Slump 41.5% Premarket to $39.71 After Co Trims FY REV Outlook
Stock Track | GeneDx Holdings Plunges 40% in Pre-Market After Q1 Revenue Miss and Drastic Full-Year Guidance Cut
Stock Track  ·  05-05
Stock Track | GeneDx Holdings Plunges 40% in Pre-Market After Q1 Revenue Miss and Drastic Full-Year Guidance Cut
U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi
Reuters  ·  05-05
U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi
Stock Track | GeneDx Holdings Plunges 42.96% After-Hours on Q1 Revenue Miss and Drastic Full-Year Guidance Cut
Stock Track  ·  05-05
Stock Track | GeneDx Holdings Plunges 42.96% After-Hours on Q1 Revenue Miss and Drastic Full-Year Guidance Cut
GeneDx Holdings Corp : Canaccord Genuity Cuts Target Price to $75 From $100
THOMSON REUTERS  ·  05-05
GeneDx Holdings Corp : Canaccord Genuity Cuts Target Price to $75 From $100
GeneDx Holdings Corp : Jefferies Cuts Target Price to $100 From $150
THOMSON REUTERS  ·  05-05
GeneDx Holdings Corp : Jefferies Cuts Target Price to $100 From $150
No data available

Introduction

Company Name.
GeneDx Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.
Issue price:
--